Sanhueza Pablo I
Obstetrics and Gynaecology Department, Health Sciences Faculty, School of Medicine, Andres Bello University, Santiago, Chile.
Fertil Steril. 2008 Nov;90(5):2015.e21-2. doi: 10.1016/j.fertnstert.2008.01.032. Epub 2008 Mar 6.
To report a case of successful use of a transdermal contraceptive in a patient with hereditary angioedema.
Case report.
University medical center.
PATIENT(S): A patient who had used oral contraceptives contracted SC and submucosal tumefaction every 1 or 2 months. She was diagnosed with type I hereditary angioedema. It was determined that she was complement C4 deficient and C1-inhibitor quantitative deficient but functional C1-inhibitor normal. After she was diagnosed, the use of oral contraceptives was contraindicated.
INTERVENTION(S): Oral contraceptives were suspended, and a hormonal transdermal contraceptive was started.
MAIN OUTCOME MEASURE(S): The absence of symptoms after 26 months using a transdermal contraceptive.
RESULT(S): After 26 months of using this treatment, the patient has not experienced any symptoms of the hereditary angioedema.
CONCLUSION(S): The use of hormonal contraceptives transdermally can be an alternative in patients with hereditary angioedema.
报告1例遗传性血管性水肿患者成功使用经皮避孕药的病例。
病例报告。
大学医学中心。
一名曾使用口服避孕药的患者每1或2个月出现皮肤和黏膜下肿胀。她被诊断为I型遗传性血管性水肿。经测定，她补体C4缺乏，C1抑制物定量缺乏，但功能性C1抑制物正常。确诊后，口服避孕药被列为禁忌。
停用口服避孕药，开始使用激素经皮避孕药。
使用经皮避孕药26个月后无症状。
使用该治疗方法26个月后，患者未出现遗传性血管性水肿的任何症状。
经皮使用激素避孕药可作为遗传性血管性水肿患者的一种替代选择。
